The phase III ToGA trial evaluated the efficacy and safety of trastuzumab in combination with chemotherapy (cisplatin plus fluorouracil or capecitabine) in patients with HER2‐positive advanced gastric adenocarcinoma [109]. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.